Publications from the National Academies of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes Health and Medicine Division (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Biomarkers of Neuroinflammation: Proceedings of a Workshop ...
Released: September 15, 2017
Innate and adaptive immunity have become very important areas of investigation for psychiatric, neurologic, and neurodevelopmental disorders, and neurodegeneration resulting from traumatic brain injury. To address these gaps in understanding mechanisms and how to translate that understanding into therapeutics, the Forum on Neuroscience and Nervous System Disorders of the National Academies of Sciences, Engineering, and Medicine convened a workshop on March 20–21, 2017, bringing together key leaders in the field from industry, academia, and governmental agencies to explore the role and mechanisms of neuroinflammation in a variety of central nervous system diseases.
Pain Management and the Opioid Epidemic: Balancing ...
Released: July 13, 2017
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016.
Therapeutic Development in the Absence of Predictive Animal ...
Released: March 10, 2017
Despite the high prevalence and burden of nervous system disorders, development of new therapeutics lags behind other disease areas. Gaps in understanding the underlying pathophysiology, a dearth of biomarkers, and limitations in the capacity of animal models to predict drug efficacy for human brain disorders have contributed to a high rate of late stage failures in drug development and decreased investment in neuroscience research programs at pharmaceutical companies. On September 12-13, 2016, the National Academies of Sciences, Engineering, and Medicine’s Forum on Neuroscience and Nervous System Disorders hosted a public workshop to explore opportunities to accelerate drug development absent predictive animal models.
The Health Effects of Cannabis and Cannabinoids: The ...
Released: January 12, 2017
In one of the most comprehensive studies of recent research on the health effects of recreational and therapeutic cannabis use, a new report from the National Academies of Sciences, Engineering, and Medicine offers a rigorous review of relevant scientific research published since 1999. This report summarizes the current state of evidence regarding what is known about the health impacts of cannabis and cannabis-derived products, including effects related to therapeutic uses of cannabis and potential health risks related to certain cancers, diseases, mental health disorders, and injuries. Areas in need of additional research and current barriers to conducting cannabis research are also covered in this comprehensive report.
International Perspectives on Integrating Ethical, Legal, and ...
Released: January 09, 2017
Emerging neurotechnologies—devices and techniques designed to collect information about the brain or affect its function—are becoming increasingly important due to scientific and technological advances and a persistent need to develop effective therapies to address the large global burden of neurological and psychiatric disease. The Organisation for Economic Co-operation and Development (OECD)—in collaboration with Arizona State University and the National Academies of Sciences, Engineering, and Medicine—held a workshop in Washington, DC, on Neurotechnology and Society: Strengthening Responsible Innovation in Brain Science.
Exploring the Development of a US Department of Labor ...
Released: December 30, 2016
More than 168 million children are affected by child labor worldwide, with a predominance of child labor occurring in sub-Saharan Africa and Asia International Labor Organization estimated in 2012 that 6 million children and more than 15 million adults were victims of forced labor. While strides have been made in understanding the problems of child labor and forced labor, as well as in approaches to reduce the global burden of both issues, additional research could help fill the remaining gaps in knowledge. To these ends, the National Academies of Sciences, Engineering, and Medicine held a workshop, at the request of the U.S. Department of Labor’s (DOL’s) Bureau of International Affairs (ILAB) Office of Child Labor, Forced Labor, and Human Trafficking (OCFT) to illuminate the current gaps in knowledge within the research fields of child labor and forced labor.
Developing Multimodal Therapies for Brain Disorders ...
Released: November 18, 2016
Califf was the keynote speaker at a workshop on multimodality therapies for brain disorders, convened by the National Academies of Sciences, Engineering, and Medicine’s Forum on Neuroscience and Nervous Systems Disorders. The workshop brought together key stakeholders to examine the general principles underlying multimodal therapies and to explore challenges, potential barriers, and opportunities for their development from multiple perspectives, including scientific, clinical, regulatory, and financial. These proceedings chronicle the presentations and discussions at the workshop.
Pain Management and Prescription Opioid-Related Harms ...
Released: November 04, 2016
The Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse was tasked with preparing a report that will identify actions that the U.S. Food and Drug Administration (FDA) and others can take to address the opioid epidemic while taking into account individual need for pain control, including FDA’s development of a formal method to incorporate the broader public health impact of prescription opioids into its future approval decisions regarding opioids.
Neuroscience Trials of the Future: Proceedings of a Workshop ...
Released: August 19, 2016
On March 3–4, 2016, the National Academies of Sciences, Engineering, and Medicine’s Forum on Neuroscience and Nervous System Disorders held a workshop in Washington, DC, bringing together key stakeholders to discuss opportunities for improving the integrity, efficiency, and validity of clinical trials for nervous system disorders.
Informing Social Security's Process for Financial Capability ...
Released: March 09, 2016
With support from SSA, the Institute of Medicine of the National Academies of Sciences, Engineering, and Medicine convened a committee to evaluate SSA’s capability determination process for adult beneficiaries with disabilities and provide recommendations for improving the accuracy and efficiency of the agency’s policy and procedures for making these determinations. In Informing Social Security’s Process for Financial Capability Determination, the committee presents a conceptual model for financial capability and reviews requisite abilities for managing or directing the management of benefits, methods and measures for assessing financial capability, the use of capacity assessment tools, and effects on the beneficiary of appointing a representative payee.